Skip to content
HealthyStudy
Menu

Comparison

Protonix vs omeprazole

Protonix

PANTOPRAZOLE SODIUM

Approved forErosive oesophagitis in GERD

Covers heartburn

Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.Label version 48, effective 18 May 2026

Omeprazole delayed-release capsules

OMEPRAZOLE

Approved forGERD, erosive oesophagitis, ulcers

Covers heartburn

Camber Pharmaceuticals, Inc.Label version 2, effective 9 January 2025

Each stripe is one section of the label, each division in a stripe one entry in that section.

Reference information, not medical advice

This page is a reference, not medical advice. It reports what the FDA-approved label states and links to that label. It does not tell anyone what to take, and it cannot replace a conversation with a doctor or pharmacist who knows the person's history.

Both are proton pump inhibitors taken by prescription, and their warning sections are close to identical. Their approved uses are not: one label runs to six indications, the other to three.

01

Side by side, straight from the labels

From the FDA label

This table is generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved.

Label sectionProtonixPANTOPRAZOLE SODIUMOmeprazole delayed-release capsulesOMEPRAZOLE
Active ingredientPantoprazoleProton pump inhibitorOmeprazoleProton pump inhibitor
Approved forErosive oesophagitis in GERDGERD, erosive oesophagitis, ulcers
SupplyPrescriptionPrescription
What pharmacies payAcquisition cost, not retail$14.23 per tablet, capsule or pen, brand$0.051 per tablet, capsule or pen, generic
Boxed warningNoneNone
What the FDA approved it for
  • Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD)
  • Maintenance of Healing of Erosive Esophagitis
  • Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) PROTONIX is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE).
  • Treatment of active duodenal ulcer in adults
  • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults
  • Treatment of active benign gastric ulcer in adults
  • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older
  • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 2 years of age and older
  • Pathologic hypersecretory conditions in adults Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H.
Forms and strengths
  • Delayed-Release Tablets: 20 mg and 40 mg pantoprazole
  • For Delayed-Release Oral Suspension: 40 mg pantoprazole
  • Omeprazole Delayed-Release Capsules: 10 mg and 20 mg
How the label says it is taken
  • Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD Adults 40 mg Once Daily for up to 8 wks Children (5 years and older) ≥ 15 kg to < 40 kg 20 mg Once Daily for up to 8 wks ≥ 40 kg 40 mg Maintenance of Healing of Erosive Esophagitis Adults 40 mg Once Daily Controlled studies did not extend beyond 12 months Pathological Hypersecretory Conditions Including...
  • 2 DOSAGE & ADMINISTRATION Indication Recommended Adult and Pediatric Dosage Treatment of Active Duodenal Ulcer 20 mg once daily for 4 weeks; some patientsmay require an additional 4 weeks H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Omeprazole delayed-release capsules amoxicillin clarithromycin 20mg 1000mg 500mg Each drug twice daily for 10 days * Dual...
Most common adverse reactions
  • Most common adverse reactions are: • For adult use (>2%): headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia.
  • Most common adverse reactions in adults (incidence ≥ 2%) are • Headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence.
  • most common adverse reactions reported (i.e., with an incidence rate ≥ 2%) from omeprazole-treated patients enrolled in these studies included headache (7%), abdominal pain (5%), nausea (4%), diarrhea (4%), vomiting (3%), and flatulence (3%).
Warnings and precautions
  • Gastric Malignancy: In adults, symptomatic response does not preclude presence of gastric malignancy. Consider additional follow-up and diagnostic testing.
  • Acute Tubulointerstitial Nephritis: Discontinue treatment and evaluate patients.
  • Clostridium difficile- Associated Diarrhea: PPI therapy may be associated with increased risk of Clostridium difficile- associated diarrhea.
  • Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine.
  • Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.
  • Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue PROTONIX and refer to specialist for evaluation.
  • Cyanocobalamin (Vitamin B-12) Deficiency: Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin.
  • Hypomagnesemia and Mineral Metabolism: Reported rarely with prolonged treatment with PPIs.
  • Gastric Malignancy: In adults, symptomatic response does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing.
  • Acute Interstitial Nephritis: Observed in patients taking PPIs.
  • Clostridium difficile -Associated Diarrhea: PPI therapy may be associated with increased risk.
  • Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine.
  • Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue omeprazole and refer to specialist for evaluation
  • Interaction with Clopidogrel: Avoid concomitant use of omeprazole.
  • Cyanocobalamin (Vitamin B-12) Deficiency: Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin.
  • Hypomagnesemia: Reported rarely with prolonged treatment with PPIs.
Contraindications
  • Patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles
  • Patients receiving rilpivirine-containing products
  • Patients with known hypersensitivity to substituted benzimidazoles or any component of the formulation.
  • Patients receiving rilpivirine-containing products.
  • Refer to the Contraindications section of the prescribing information for clarithromycin and amoxicillin, when administered in combination with omeprazole delayed-release capsules.
Drug interactions
  • There are other antiretroviral drugs which do not result in clinically relevant interactions with pantoprazole. Intervention: Rilpivirine-containing products: Concomitant use with PROTONIX is contraindicated. See prescribing information. Atazanavir: See prescribing information for atazanavir for dosing information. Nelfinavir: Avoid concomitant use with PROTONIX.
  • There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole. Intervention: Rilpivirine-containing products: Concomitant use with omeprazole is contraindicated. Atazanavir: Avoid concomitant use with omeprazole. See prescribing information for atazanavir for dosing information. Nelfinavir: Avoid concomitant use with omeprazole.
Label version18 May 20269 January 2025

Comparison of Protonix vs omeprazole taken from the FDA labels.

02

The approved uses are not the same length

Written by us

The prescription omeprazole label lists active duodenal ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, active benign gastric ulcer, symptomatic GERD, erosive oesophagitis due to acid-mediated GERD, and pathological hypersecretory conditions.

The Protonix label lists three: short-term treatment of erosive oesophagitis associated with GERD, maintenance of healing of erosive oesophagitis, and pathological hypersecretory conditions including Zollinger-Ellison syndrome. Ulcers and H. pylori do not appear.

03

One of them can be bought without a prescription, the other cannot

Written by us

Omeprazole holds a second, separate approval as Prilosec OTC, a 20 mg tablet sold for a 14-day course against frequent heartburn. Esomeprazole and lansoprazole have equivalents. Pantoprazole has none: in the United States it exists only as a prescription medicine.

That is a regulatory fact rather than a statement about strength or safety, and neither label comments on it.

04

The class warnings are the same in both

Written by us

Both labels warn that a symptomatic response does not rule out gastric malignancy, that acute tubulointerstitial nephritis has occurred and treatment should be discontinued if it does, that proton pump inhibitor therapy may be associated with an increased risk of Clostridium difficile-associated diarrhoea, and that long-term or multiple daily dose therapy may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist or spine.

Warnings repeated word for word across products of one class are class warnings. They say something about proton pump inhibitors generally rather than about either product in particular.

05

The ages covered differ

Written by us

The omeprazole label covers GERD and erosive oesophagitis in patients 2 years of age and older. The Protonix dosing section covers adults and children from 5 years of age and 15 kg upward for erosive oesophagitis associated with GERD.

Both labels give their dosing by indication rather than as a single dose, which is the practical difference from any over-the-counter product in this class.

06

Common questions

Written by us
Is pantoprazole available over the counter?
Not in the United States. Omeprazole, esomeprazole and lansoprazole each hold a separate over-the-counter approval; pantoprazole is prescription only.
Which is stronger, Protonix or omeprazole?
The labels do not compare them and this page does not rank them. They differ in approved uses: omeprazole covers ulcers and H. pylori eradication, which the Protonix label does not.
Do both carry the same warnings?
The main warnings are the same and appear in near-identical wording: gastric malignancy not excluded by symptom relief, acute tubulointerstitial nephritis, Clostridium difficile-associated diarrhoea, and fracture risk with long-term or multiple daily dose therapy.
07

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

Other comparisons in this category

Page last updated: 11 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.